✦ LIBER ✦

941 JTK-652 IS A NOVEL HCV ENTRY INHIBITOR: RESULTS OF A PHASE 1 STUDY EVALUATING SAFETY, TOLERABILITY AND ANTIVIRAL ACTIVITY IN CHRONIC HEPATITIS C PATIENTS

✍ Scribed by J. de Bruijne; J. Bergmann; C. Weegink; K. van Nieuwkerk; R. de Knegt; J. van de Wetering de Rooij; A. van Vliet; R. Molenkamp; J. Schinkel; H. Reesink; H. Janssen

Book ID: 117377945
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 48 KB
Volume: 50
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(09)60943-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

92 SAFETY, TOLERABILITY AND ANTIVIRAL AC

92 SAFETY, TOLERABILITY AND ANTIVIRAL ACTIVITY OF VCH-916, A NOVEL NON-NUCLEOSIDE HCV POLYMERASE INHIBITOR IN PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION

✍ E. Lawitz; C. Cooper; M. Rodriguez-Torres; R. Ghalib; R. Lalonde; A. Sheikh; B. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB

2003 ANTIVIRAL ACTIVITY, PHARMACOKINETIC

2003 ANTIVIRAL ACTIVITY, PHARMACOKINETICS, AND TOLERABILITY OF AZD7295, A NOVEL NS5A INHIBITOR, IN A PLACEBO-CONTROLLED MULTIPLE ASCENDING DOSE STUDY IN HCV GENOTYPE 1 AND 3 PATIENTS

✍ Gane, E.; Foster, G.R.; Cianciara, J.; Stedman, C.; Ryder, S.; Buti, M.; Clark, 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 100 KB

A phase 2 study to evaluate the antivira

A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients

✍ Vincent G. Bain; Kelly D. Kaita; Eric M. Yoshida; Mark G. Swain; E. Jenny Heathc 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 198 KB

294 Safety and antiviral effect of BILN

294 Safety and antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, genotype 1, and liver cirrhosis

✍ Heiner Wedemeyer; Andreas Erhardt; Wolff Schmiegel; Holger Hinrichsen; Ricardo C 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB